Living Models (formerly .omics)

Name: Living Models (formerly .omics)
Brand: Living Models

AI Native

Foundation Models for Living Systems

Est 2024

LinkedIn 1K|Website|FTEs 14

Living Models (formerly .omics) screenshot

01Competitive Landscape

Narrative analysis

Potential strengths: - Focus on plant foundation models with stated pretraining across multiple species and genomes. - Licensing model that, according to company statements, permits customers to fine-tune in controlled environments. Where alternatives may offer advantages: - Some competitors publish benchmarks, datasets, and integration artifacts that support auditability and adoption. - Large incumbents may provide more end-to-end operational integration (trial management, field phenotyping, supply-chain linkages) even if they do not sell foundation models as a standalone product. Market adoption notes: - The plant genomics foundation-model segment is active and evolving; differentiation will depend on demonstrable improvements in breeder workflows, documented validation, and enterprise readiness.

	Living Models (BOTANIC)	InstaDeep (Nucleotide Transformers / AgroNT / NTv3)	Evogene (GeneRator AI)
Starting Price	Not publicly listed (enterprise licensing implied)	Not publicly listed (mix of open releases + enterprise)	Not publicly listed (platform economics described in public filings)
Best For	Seed/breeding organizations seeking cross-species genomic representation learning and in-house fine-tuning	Teams seeking well-documented genomics foundation models with public benchmarks and datasets	Organizations seeking an AI-driven discovery platform across ag-biological domains (traits / crop inputs)
Key Strength	Early open-weight plant genome models; company states that data remains with the customer; plant-focused pretraining claims	Public research outputs, benchmark artifacts, and dataset openness; established enterprise collaborations	Broader crop/biological discovery stack and continuity as a public company; integration with regulated reporting
Key Weakness	Limited public enterprise security/compliance information; limited third-party validation; research-only license restricts production use without negotiation	May prioritize large enterprise partnerships over small programs; engagement model may not suit all teams	Not positioned solely as a plant genomic foundation model; platform complexity and cost can be barriers

01Competitive Landscape

Narrative analysis

Potential strengths:

Focus on plant foundation models with stated pretraining across multiple species and genomes.
Licensing model that, according to company statements, permits customers to fine-tune in controlled environments.

Where alternatives may offer advantages:

Some competitors publish benchmarks, datasets, and integration artifacts that support auditability and adoption.
Large incumbents may provide more end-to-end operational integration (trial management, field phenotyping, supply-chain linkages) even if they do not sell foundation models as a standalone product.

Market adoption notes:

The plant genomics foundation-model segment is active and evolving; differentiation will depend on demonstrable improvements in breeder workflows, documented validation, and enterprise readiness.

	Living Models (BOTANIC)	InstaDeep (Nucleotide Transformers / AgroNT / NTv3)	Evogene (GeneRator AI)
Starting Price	Not publicly listed (enterprise licensing implied)	Not publicly listed (mix of open releases + enterprise)	Not publicly listed (platform economics described in public filings)
Best For	Seed/breeding organizations seeking cross-species genomic representation learning and in-house fine-tuning	Teams seeking well-documented genomics foundation models with public benchmarks and datasets	Organizations seeking an AI-driven discovery platform across ag-biological domains (traits / crop inputs)
Key Strength	Early open-weight plant genome models; company states that data remains with the customer; plant-focused pretraining claims	Public research outputs, benchmark artifacts, and dataset openness; established enterprise collaborations	Broader crop/biological discovery stack and continuity as a public company; integration with regulated reporting
Key Weakness	Limited public enterprise security/compliance information; limited third-party validation; research-only license restricts production use without negotiation	May prioritize large enterprise partnerships over small programs; engagement model may not suit all teams	Not positioned solely as a plant genomic foundation model; platform complexity and cost can be barriers

Living Models (formerly .omics)

01Competitive Landscape

Narrative analysis

02Market Map

01Competitive Landscape

Narrative analysis

02Market Map